Found 652 with Last Name = 'grewal' and Initial = 'gs' TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 5.80nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 5.80nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.
US Patent
The Brigham and Women's Hospital, Inc.
US Patent
Affinity DataIC50: 6.5nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.
US Patent
The Brigham and Women's Hospital, Inc.
US Patent
Affinity DataIC50: 6.5nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 7.70nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 7.70nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 8nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 8nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 8.60nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 8.60nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.
US Patent
The Brigham and Women's Hospital, Inc.
US Patent
Affinity DataIC50: 9.10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.
US Patent
The Brigham and Women's Hospital, Inc.
US Patent
Affinity DataIC50: 9.10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.
US Patent
The Brigham and Women's Hospital, Inc.
US Patent
Affinity DataIC50: 9.20nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 11nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 11nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 12nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 12nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 14nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 14nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 15nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 15nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 15nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 15nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 17nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 17nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 17nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 17nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 19nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 19nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 19nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 19nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
